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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a hyperin-
flammatory condition presenting with fever,
hepatosplenomegaly, and cytopenia. Untreated, the full pic-
ture of HLH is fatal. In most cases of hereditary HLH,
hematopoietic stem cell transplantation (HSCT) must follow
a remission induction therapy to prevent reactivations.
Busulfan-based myeloablative conditioning regimens for
HSCT in HLH are associated with high transplant-related
mortality and particularly high incidence of veno-occlusive
disease (VOD).1,2 Melphalan-based reduced intensity condi-
tioning (RIC) regimens have substantially improved overall
survival.3-6 Remaining issues are a high rate of mixed
chimerism requiring donor lymphocyte infusions (DLI) with
a substantial rate of subsequent graft-versus-host disease
(GvHD) and fatal infections due to prolonged immunosup-
pression.5 We hypothesized that treosulfan (with addition of
thiotepa in selected patients) might be more lymphotoxic and
myelosuppressive than melphalan and still produce less
adverse effects than myeloablative busulfan.
Methods
In this retrospective multicenter study, we assessed survival,
engraftment, donor chimerism, disease reactivation, and adverse
events after HSCT. Inclusion criteria were: 1) a known hereditary
defect predisposing to HLH, i.e. familial HLH (FHL2-5), X-linked lym-
phoproliferative syndrome (XLP) type 1, deficiency of X-linked
inhibitor of apoptosis (XIAP), Griscelli syndrome 2, and Chediak-
Higashi syndrome, or if no genetic defect was identifiable, a degranu-
lation defect as determined by the CD107 assay in resting NK cells;7
2) the administration of an HSCT conditioning regimen containing
fludarabine (150-180 mg/m² or 5-6 mg/kg), treosulfan (42 g/m² or 36
g/m² if <12 kg), and facultative thiotepa (10 mg/kg or 7 mg/kg if <12
kg). Alemtuzumab was administered at a dose of 0.3-1.0 mg/kg.
Addition of thiotepa was dependent on center preference, in particu-
lar in patients at risk, most importantly absence of full remission as
defined elsewhere2 and less frequently an HLA-mismatched (9/10)
donor transplant. The decision of centers to apply this regimen was
based on favorable experience with treosulfan-based conditioning in
other diseases.8 Patients from centers applying different regimens, e.g.
use of ATG or melphalan, were not included. Any patient age, donor
type, or stem cell source was eligible. Central nervous system involve-
ment was defined as published earlier.9 Nineteen patients from 9
German centers (6 patients from 1 center, 3 patients from 1, 2 patients
each from 3, and 1 patient each from 4 centers), who underwent
HSCT between June 2010 and December 2012, were analyzed.
Statistics and ethical considerations
Differences in distribution were compared in a 2-step approach. 1)
Three potential risk factors (donor type, remission, and  administra-
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In hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis, high transplant-related mortal-
ity after busulfan-based myeloablative regimens has been observed. Conditioning regimens with reduced toxicity
based on melphalan or treosulfan are promising alternatives. We retrospectively analyzed hematopoietic stem cell
transplantations in 19 hemophagocytic lymphohistiocytosis patients after conditioning with fludarabine, treosulfan,
alemtuzumab, with or without thiotepa. Overall and disease-free survivals were 100% (follow up 7-31 months). Two
patients required second transplant (1 after haploidentical transplantation). In 6 patients, overall donor chimerism
dropped below 75% and prompted donor lymphocyte infusions. Administration of donor lymphocytes or second
transplantation were significantly more frequent after transplantation from a human leukocyte antigen mismatched
(9/10) versus matched (10/10) donor (P=0.018). The toxicity profile was favorable, with one veno-occlusive disease,
one grade 3 graft-versus-host disease after donor lymphocyte infusion, and 2 severe viral infections (1 influenza, 1
Epstein Barr virus). In conclusion, the treosulfan-based regimen in hemophagocytic lymphohistiocytosis is effective
with low toxicity and gives excellent overall and disease-free survival rates. In the future, the incidence of mixed
chimerism, particularly after human leukocyte antigen mismatched donor transplants, needs to be addressed. 
ABSTRACT
tion of thiotepa) for post-HSCT cellular therapy (DLI, second
HSCT, stem cell boost) were each tested in a univariate model
using two-tailed Fisher’s exact test with calculation of the odds
ratio as estimator of effect. The variable with the poorest correla-
tion as judged by the odds ratio and the P value was excluded from
further analyses. Second, a multivariate analysis with the remain-
ing variables was performed with a logistic regression model, cal-
culating odds ratio, 95% confidence interval, and P value. P <0.05
was considered significant. Calculations were performed using
PASW statistics 18 (IBM SPSS). One haploidentical HSCT was
excluded from this analysis. Patients or legal guardians had given
their written informed consent in accordance with the Declaration
of Helsinki. The study was approved by the ethical review board
of the Hamburg Chamber of Physicians.
Results 
Patients’ characteristics, conditioning regimen and
GvHD prophylaxis   
Patients’ and HSCT characteristics are listed in Table 1.
The cohort included 6 different known genetic defects.
Median age at HSCT was 3.9 years (range 0.3-22 years),
with 6 infants (< 12 months) and 2 young adults (≥ 18
years). Particular features were FHL5-related enteropathy
in 2 patients, XIAP deficiency related chronic inflammato-
ry bowel disease (IBD) in 2 patients, and Hodgkin’s dis-
ease two years prior to HSCT in one patient. Most
patients had received the HLH2004 protocol as first-line
therapy. Two patients were transplanted before the
appearance of HLH; one patient with Griscelli syndrome
type 2 and one patient with XIAP deficiency for whom
HSCT was performed for intractable inflammatory bowel
disease. Select aspects of 3 XIAP deficiency patients10 and
5 FHL5 patients11 are included in other reports.
A fludarabine dose of 150 mg/m² or 5 mg/kg was
administered to 16 patients from Day -7 until Day -3 (±1
day). Three patients received 160-180 mg/m² or 6 mg/kg
from Day -8 until Day -3 (±1 day). All patients received
treosulfan at a dose of 42 g/m² (or 36 g/m² if <12 kg) from
Day -6 until Day -4 (±1 day). Thiotepa at a dose of 10
mg/kg (or 7 mg/kg if <12 kg), given on Day -3 (±1 day)
divided in two doses, was added in 14 patients. 
Alemtuzumab was administered in all patients: 0.8-1.0
mg/kg for HLA-mismatched donor (9/10) transplants
and/or patients in non-remission, n=10; 0.3-0.4 mg/kg in
HLA-matched (10/10) sibling donor transplants for
patients in remission, n=4; 0.5-1.0 mg/kg for HLA-
matched (10/10) unrelated donor transplants for patients
in remission, n=5. In the patient who received a CD34+
selected haploidentical graft, alemtuzumab was given pri-
marily to treat persistent HLH activity and prevent rejec-
tion. Cumulative alemtuzumab doses of 0.4 mg/kg or over
were divided in daily doses of 0.2 mg/kg/d (n=16), 4 of
which starting with 0.05 or 0.1 mg/kg/d; 0.3 mg/kg were
administered in daily doses of 0.1 mg/kg/d (n=3). In 17
patients, the antibody was given prior to HSCT (first day
ranging from -10 to -4, last day ranging from -7 to -1) and
in another 2, alemtuzumab was infused until Day +1. 
The following drug combinations for post-HSCT GvHD
prophylaxis were applied: ciclosporin A (CSA) and
methotrexate (n=9, in 1 of whom CSA was substituted by
MMF on Day 49 due to poor tolerability); CSA and MMF
(n=7); CSA only (n=2); tacrolimus and MMF due to poor
tolerability of CSA during primary HLH therapy (n=1),
and MMF only in 1 haploidentical HSCT with a CD34+
selected graft. CSA and tacrolimus administration started
on Day -1, targeting at trough levels of 80-180 mg/L and 8-
12 µg/L, respectively, which were terminated at a median
of 105, range 35-703 days. MTX was infused on Days +1,
+3 and +6 at a dose of 10 mg/m². MMF was given from
Day -1 at a dose of 45 mg/kg/d or 1200 mg/m²/d.
Overall outcome
Both overall survival and disease-free survival were
100% with a follow up of 7-31 months (median 16
months). The last Lansky/Karnofsky score was 90-100%
in 18 patients and 60% in one patient due to pre-existing
neurological deficits. However, the FHL5-related
enteropathy persisted in both patients, as described previ-
ously.11 In both patients with IBD due to XIAP-deficiency,
inflammatory activity ceased after HSCT.
Engraftment, chimerism, immune reconstitution, 
and subsequent cell therapy
Primary leukocyte engraftment (>1000/mL) was success-
ful in all patients at a median of 20 days (range 11-62
days). Two patients required a second HSCT, one at Day
33 for early graft rejection after haploidentical HSCT
(CD34 positive-selected peripheral stem cell graft) and one
at Day 125 for secondary graft failure. In the remaining 17
patients, overall donor chimerism was complete (>95%)
in 5 patients, dropped to 75-95% in 6 (3 of which returned
to full chimerism and 3 remained stable after reduction of
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Table 1. Patients’ characteristics.
N. %
Total 19 100





Griscelli syndrome type 2 1 5
XLP 1 5
XIAP deficiency 3 16
Undefined degranulation defect 2 11
Therapy prior to HSCT
HLH2004 13 68
CSA and corticosteroids 2 11
Corticosteroids only 2 11
Therapy for IBD 1 5
None 1* 5
Addition of rituximab 2 11
CNS involvement 6 32
Non-remission of HLH 7 37
Donor
HLA-mismatched (9/10) 7† 37
Unrelated HLA-matched (10/10) 6 32
Related HLA-matched (10/10) 5 26
Haploidentical 1 5
Stem cell source
Bone marrow 17 89
PBSC 2 11
*In the Griscelli syndrome type 2 patient, HSCT was performed before the first flare of
HLH. †This cohort comprises 6 unrelated and 1 related donors, all HLA-mismatched
(9/10). FHL: familial HLH; XLP: X-linked lymphoproliferative syndrome; XIAP: X-linked
inhibitor of apoptosis; IBD: inflammatory bowel disease; CNS: central nervous system;
PBSC: peripheral blood stem cells.  
immunosuppression), and decreased to a nadir of 20-74%
in 6 patients. In the latter, DLI led to stabilization of donor
chimerism in 3 (1 of which with a single stem cell boost)
and reversion to full donor chimerism in 2 patients; one
patient is scheduled for DLI. At last follow up (median
408, range 196-847 days), overall donor chimerism was
complete in 10, 75-95% in 3, and 20-74% in 4 patients.
CD3+ T-cell counts over 500/mL were achieved after a
median of 162 days (n=12). 
DLI, stem cell boost, or second HSCT were required in
42% of patients in our cohort (Table 2). Importantly, 5 out
of 6 patients requiring DLI and one patient with secondary
graft failure originated from the group of 7 patients with
an HLA-mismatched (9/10) donor, and the graft rejection
occurred after haploidentical HSCT. The haploidentical
HSCT was excluded from the evaluation of potential risk
factors for post-HSCT cellular therapy. In the univariate
analysis (donor type (HLA-matched 10/10 vs. HLA-mis-
matched 9/10), administration of thiotepa, and remission
status), non-remission was identified as not significant
(P=0.62). While the univariate analysis rendered P values
of 0.002 for an HLA-mismatched (9/10) donor and 0.047
for a conditioning regimen without thiotepa, the subse-
quent multivariate model showed only for the risk factor
donor type a significant effect (P=0.018) with an odds ratio
of 38.9. The effect of thiotepa (odds ratio 4.6) was not sig-
nificant in the multivariate analysis (P=0.389). 
Toxicity, infection and GvHD
Sixteen patients received either defibrotide12 (n=9)
and/or heparin (n=9) prophylaxis for veno-occlusive dis-
ease (VOD). Only one hepatic VOD developed in the hap-
loidentical HSCT, despite defibrotide. Further serious
adverse events included life threatening hemorrhage
(n=2), mucositis grade 3 or 4 (n=2), and skin toxicity grade
3 (n=3, 2 of whom had received thiotepa). Five bac-
teremias were detected, one of which with clinical sep-
ticemia, and 3 possible fungal infections. Post-HSCT
Epstein-Barr viremia occurred in 2 patients, requiring rit-
uximab in one. Systemic cytomegalovirus (n=3), herpes
simplex virus (n=3), adenovirus (n=1), human herpes virus
6 (n=1), and influenza A (n=2) were detected, leading to
major complications only in one case of influenza (pul-
monary hemorrhage, extracorporal membrane oxygena-
tion). BK virus was found in the urine in 3 and herpes
zoster developed in 3 patients. Intubation was necessary
in 3 patients (influenza, bleeding, and septicemia). Only
one acute grade 3 GvHD after DLI (skin, gastointestinal,
liver) and 4 grade 1 or 2 GvHD occurred, none resulted in
long-term sequelae or chronic GvHD.
Discussion
The overall and disease-free survivals of 100% (n=19) in
this cohort suggest the treosulfan-based conditioning as an
alternative to the mostly melphalan-based RIC, which
gave similar results with overall survival of 84% (n=25)4
and 92% (n=26).5  In a study on umbilical cord blood trans-
plantation in HLH patients after RIC including melphalan
and low-dose total body irradiation in some cases, overall
survival was 91% (n=11).6 A broad spectrum of underlying
genetic defects is covered in the analysis, demonstrating
the efficacy in various subtypes of hereditary HLH, includ-
K. Lehmberg et al.
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Table 2. Comparison of risk factors for second HSCT, DLI, and stem cell boost.
Univariate Multivariate
Total N. % N. % odds ratio P value Odds ratio 95% CI P
19 100
2nd HSCT 2 11
DLI 6*† 32
Any additional cellular therapy 8 42
Donor type HLA-mis- HLA-
matched matched
(9/10) (10/10)
7 100 11 100
2nd HSCT 1 14 0 0
DLI 5* 71 1† 9
Any additional cellular therapy 6 86 1 9 60 0.002 38.9 1.9-816.2 0.018
Conditioning Without With
thiotepa thiotepa
5 100 13 100
2nd HSCT 0 0 1 8
DLI 4 80 2*† 15
Any additional cellular therapy 4 80 3 23 13.3 0.047 4.6 0.1-143.5 0.389
Remission status Non- Remission
remission
6 100 12 100
2nd HSCT 1 17 0 0
DLI 2 33 4*† 33
Any additional cellular therapy 3 50 4 33 2.0 0.62 ND ND ND
The prevalence of post-HSCT cellular therapy (DLI, stem cell boost, and 2nd HSCT) was analyzed for the whole cohort. To identify potential risk factors, the haploidentical HSCT was
excluded and a 2-step approach was performed, After univariate analysis, non-remission was excluded from further analysis, as it showed little correlation as judged by the odds
ratio and the P-value.  Subsequently, a multivariate analysis of donor type (HLA-mismatched 9/10 vs. HLA-matched 10/10) and application of thiotepa identified an HLA-mismatched
donor as a significant independent risk factor. *One patient was administered both DLI and a stem cell boost. † In 1 patient of this cohort, DLI has not been administered yet, but
is scheduled. CI: confidence interval; ND: not done.
ing XIAP-deficiency for which overall survival was report-
ed to be poor in a previous study, particularly in patients
in non-remission: 14% after myeloablative conditioning
(n=7) and 50% after RIC with fludarabin, melphalan, and
alemtuzumab (n=10).10 Treosulfan has previously been
proven to be a safe and effective conditioning agent for
malignant and non-malignant disease.8,13,14 However, pre-
vious experience with treosulfan, fludarabine, and alem-
tuzumab in HLH was anecdotal. In a series of immunode-
ficiencies, 3 of 4 HLH patients died,15 whereas 2 patients in
another cohort are long-term survivors.16
The rate of additional cellular therapy after first HSCT
(including second HSCT, administration of DLI, and stem
cell boost) was high in the cohort with HLA-mismatched
(9/10) donors (86%) while it was only 9% if the donor
was HLA-matched (10/10) (P=0.018). This finding particu-
larly points to the need to optimize the conditioning regi-
men for HLA-mismatched HSCT. Since at least in the uni-
variate test, sustained engraftment in patients who had
received thiotepa was superior, the addition of this drug to
the regimen may be an option. However, this finding did
not reach the level of significance in the multivariate
model and thus requires further confirmation. In the liter-
ature, melphalan-based RIC resulted in mixed chimerism
in 6 of 21 (29%)4 and 14 of 26 (54%)5 surviving patients. In
a cohort with cord blood SCT after melphalan-based RIC,
2 of 10 (20%) surviving patients required second trans-
plant and another 2 (20%) had mixed chimerism and late
graft failure.6 To date, the degree of donor chimerism
required in humans to prevent recurrence of HLH is not
entirely clear.
Serotherapy in HSCT is a matter of debate. We have
decided to use alemtuzumab because it was reported to
induce remission after failure of primary HLH therapy17
and had successfully been used in previous RIC regimens
for HLH.4,5 A beneficial effect of alemtuzumab in HSCT
for HLH is assumed due to the wide distribution of CD52,
including T cells and antigen-presenting cells, potentially
suppressing remaining disease activity, which is relevant
in particular for patients in non-remission.5 Despite slow
T-cell reconstitution, the rate of relevant complications
due to virus reactivations and infections was low. The pre-
viously reported high incidence of viral infections after
alemtuzumab18 has been attributed to an estimated half-
life of 15-21 days, implying that active antibodies may
persist for several months.19 Given the low incidence of
acute and chronic GvHD in the present study, a dose
reduction of alemtuzumab in HLA-mismatched donor
transplants may be another option to reduce the rate of
mixed chimerism. A different approach may be the appli-
cation of alemtuzumab three weeks prior to HSCT.5
Unlike most other immunodeficiencies, HLH is associat-
ed with severe complications in HSCT after myeloablative
conditioning due to the hyperinflammatory nature of the
condition. As in previous reports on RIC in HLH,3,5 the rate
of VOD was low in our analysis. However, it must be kept
in mind that defibrotide and/or heparin were given as
VOD prophylaxis. Defibrotide has been shown to protect
against VOD after myeloablative conditioning if at least
one risk factor for VOD was present; the risk factors
included HLH as underlying condition and the use of
busulfan or melphalan.12 The occurrence of grade 3 skin
toxicities in 3 patients is likely to be due to the use of tre-
osulfan and thiotepa, and underscores the importance of
attention to skin care, including frequent washing during
application of thiotepa. 
Pre-HSCT characteristics of patients in the present
cohort were comparable to most previous reports. Median
age at HSCT (3.9 years) in the present cohort was in the
same range as in the recent report5 on melphalan-based
RIC (5 years). Patients in earlier reports were younger at
HSCT (6-14 months).2,3,20 This may reflect the increasing
awareness of hereditary forms of HLH beyond infancy.21
The rate of patients in non-remission (37% in this report)
was 8-47% in other reports1-3,5,6,20 and the incidence of CNS
involvement at any time prior to transplant (32% in this
report) is similar to most of these other reports1-3,5,6 at 23-
41%; in only one study was this rate substantially higher
at 80%.20 
In conclusion, fludarabine, treosulfan, alemtuzumab,
and thiotepa represent a conditioning regimen with a high
rate of overall and disease-free survival and low toxicity in
the complication-prone group of patients with hereditary
HLH. In recipients of a graft from an HLA-mismatched
donor, the rate of primary complete donor chimerism
requires improvement, e.g. by inclusion of thiotepa and/or
adjustment of serotherapy.
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